An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients
An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients
复制标题
DOI:
10.1007/s11306-019-1522-5
复制
发表时间:
2019-05-01
期刊:
影响因子:
3.6
通讯作者:
Namer, Izzie Jacques
中科院分区:
文献类型:
--
作者:
Bund, Caroline;Guergova-Kuras, Mariana;Namer, Izzie Jacques
IntroductionThe identification of frequent acquired mutations shows that patients with oligodendrogliomas have divergent biology with differing prognoses regardless of histological classification. A better understanding of molecular features as well as their metabolic pathways is essential.ObjectivesThe aim of this study was to examine the relationship between the tumor metabolome, six genomic aberrations (isocitrate dehydrogenase1 [IDH1] mutation, 1p/19q codeletion, tumor protein p53 [TP53] mutation, O-6-methylguanin-DNA methyltransferase [MGMT] promoter methylation, epidermal growth factor receptor [EGFR] amplification, phosphate and tensin homolog [PTEN] methylation), and the patients' survival time.MethodsWe applied H-1 high-resolution magic-angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy to 72 resected oligodendrogliomas.ResultsThe presence of IDH1, TP53, 1p19q codeletion, MGMT promoter methylation reduced the relative risk of death, whereas PTEN methylation and EGFR amplification were associated with poor prognosis. Increased concentration of 2-hydroxyglutarate (2HG), N-acetyl-aspartate (NAA), myo-inositol and the glycerophosphocholine/phosphocholine (GPC/PC) ratio were good prognostic factors. Increasing the concentration of serine, glycine, glutamate and alanine led to an increased relative risk of death.ConclusionHRMAS NMR spectroscopy provides accurate information on the metabolomics of oligodendrogliomas, making it possible to find new biomarkers indicative of survival. It enables rapid characterization of intact tissue and could be used as an intraoperative method.